We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

120 hedge funds and large institutions have $252M invested in Aldeyra Therapeutics in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 41 increasing their positions, 37 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 37

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

1% more funds holding

Funds holding: 119120 (+1)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

2.18% less ownership

Funds ownership: 66.64%64.46% (-2.2%)

23% less capital invested

Capital invested by funds: $328M → $252M (-$75.2M)

38% less call options, than puts

Call options by funds: $1.34M | Put options by funds: $2.16M

Holders
120
Holders Change
+1
Holders Change %
+0.84%
% of All Funds
1.9%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
41
Reduced
37
Closed
14
Calls
$1.34M
Puts
$2.16M
Net Calls
-$820K
Net Calls Change
+$2.53M
Name Holding Trade Value Shares
Change
Change in
Stake
Osaic Holdings
51
Osaic Holdings
Arizona
$309K +$291K +39,166 +548%
D.E. Shaw & Co
52
D.E. Shaw & Co
New York
$307K -$223K -30,013 -40%
PA
53
Profund Advisors
Maryland
$301K -$5.74K -773 -2%
IAIM
54
International Assets Investment Management
Florida
$299K +$5.16K +695 +1%
AAA
55
Affinity Asset Advisors
New York
$296K -$784K -105,652 -70%
WMSA
56
Weiss Multi-Strategy Advisers
New York
$292K -$46.6K -6,277 -13%
AA
57
ALPS Advisors
Colorado
$289K +$1.43K +192 +0.4%
State of Wisconsin Investment Board
58
State of Wisconsin Investment Board
Wisconsin
$268K -$6.88K -927 -2%
T. Rowe Price Associates
59
T. Rowe Price Associates
Maryland
$267K +$5.5K +742 +2%
Victory Capital Management
60
Victory Capital Management
Texas
$267K -$1.06M -142,520 -78%
Legal & General Group
61
Legal & General Group
United Kingdom
$251K -$2.25K -303 -0.8%
First Manhattan
62
First Manhattan
New York
$232K
Parallax Volatility Advisers
63
Parallax Volatility Advisers
California
$229K +$85.5K +11,529 +51%
TFA
64
Tobias Financial Advisors
Florida
$228K
FRM
65
Fox Run Management
Connecticut
$224K +$249K +33,519 New
Mirae Asset Global Investments
66
Mirae Asset Global Investments
South Korea
$215K -$126 -17 -0.1%
JP Morgan Chase
67
JP Morgan Chase
New York
$213K -$33.4K -4,504 -12%
CAPTRUST Financial Advisors
68
CAPTRUST Financial Advisors
North Carolina
$203K +$114K +15,339 +102%
JPLA
69
Joseph P. Lucia & Associates
New York
$189K +$41.2K +5,550 +24%
JGC
70
J. Goldman & Co
New York
$180K -$601K -81,000 -75%
Stifel Financial
71
Stifel Financial
Missouri
$169K -$100K -13,494 -35%
Janus Henderson Group
72
Janus Henderson Group
United Kingdom
$169K +$52 +7 +0%
MIM
73
MetLife Investment Management
New Jersey
$165K
OQS
74
Occudo Quantitative Strategies
Florida
$159K +$176K +23,748 New
SO
75
STRS Ohio
Ohio
$157K

ALDX Hedge Fund Activity: Q3 2023 in Review

120 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2023, worth a combined $252M — down 23% from $328M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ALDX positions and 14 closed out — a net gain of 1 holder — while 41 added to existing stakes and 37 trimmed.

The largest buyer was BlackRock, adding an estimated $1.04M. The largest seller was Fidelity Investments, cutting an estimated $5.02M.

  • 120 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2023, up from 119 in Q2 2023.
  • Funds reported $252M of Aldeyra Therapeutics stock for Q3 2023, down 23% quarter-over-quarter.
  • 15 funds opened new Aldeyra Therapeutics positions in Q3 2023 and 14 closed out, a net change of +1 holder.
  • The largest Aldeyra Therapeutics buyer in Q3 2023 was BlackRock, an estimated $1.04M added.
  • The largest Aldeyra Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $5.02M sold.

Based on aggregated 13F filings for Q3 2023.